Conviction: Medium (tempered by persistent data staleness and ongoing insider selling)
Status: Data stale — RSI 8.8 (as of Feb 5), price $476.32 per last data. Actual current price unknown.
Quick Snapshot
| Signal |
Reading |
| Overall |
🟢 RSI 8.8 (stale — last updated Feb 5, 2026) — still the most extreme reading in our universe if accurate. Price $476.32 per stale data. -5.5% in 7 days per available data. Need fresh data urgently. |
| Moat |
Wide (surgical robotics monopoly — da Vinci system) |
| Key insight |
OHLC data has been stale since Feb 5, 2026 — now nearly 4 weeks without an update. This is the most pressing data quality issue in our coverage. Real-time price could be materially different from the $476.32 stale figure. RSI 8.8 sustained for 4+ weeks would be historically unprecedented — or the data is simply not refreshing. Da Vinci monopoly thesis remains unquestionably intact. |
Action Matrix
| Action |
Level |
Why |
| Current |
⏳ Wait for fresh data |
Cannot act responsibly without current RSI/price. Fetch data first. |
| If fresh RSI still < 15 |
✅ Buy (small) |
RSI extreme + monopoly moat = strong signal |
| If fresh RSI 15-30 |
📈 Accumulate |
Still oversold; reduced urgency |
| If fresh RSI > 30 |
🔍 Watch |
Recovery underway; wait for new entry point |
| Entry Zone (if still oversold) |
$455 - $490 |
Based on stale data — verify with fresh price |
| Stop-Loss |
$405 (-15%) |
Below key support |
| Target |
$600 (+26%) |
Recovery toward recent levels |
Price Data
| Stock |
Price |
1D |
7D |
30D |
3M |
52wkHi |
RSI |
Status |
Action |
| ISRG |
$476.32* |
-0.5%* |
-5.5%* |
-19.6%* |
-13.0%* |
-19.7%* |
8↓* |
🟢 Extreme Oversold* |
⏳ Fetch Fresh Data |
All values from stale OHLC data (last entry: Feb 5, 2026). Treat as outdated.
Price vs Last Deep Dive (02/26)
| Metric |
02/26 |
03/03 |
Change |
| Price |
$476.32 |
$476.32 |
$0.00 (OHLC data unchanged — STALE) |
| RSI |
8.8 |
8.8 |
0.0 (stale — 4+ weeks without update) |
| SMA20 |
$527.40 |
$527.40 |
Unchanged (stale) |
| vs SMA |
-9.7% |
-9.7% |
Stale |
Update (03/03): ISRG OHLC data remains stuck at Feb 5, 2026. This is now the 4th consecutive weekly review showing identical data. Real-time price action is unknown. The 7D reading (-5.5%) in the stale data suggests ongoing selling pressure as of the last valid date. The da Vinci monopoly thesis has not changed. Insider selling ($282.6M) was the key overhang as of last real data.
Company Overview
One-Liner
Intuitive Surgical manufactures and sells the da Vinci robotic surgical system, with a near-monopoly in soft-tissue robotic surgery globally.
Business Model
| Question |
Answer |
| What they sell |
da Vinci surgical systems (hardware), instruments/accessories (per-procedure), service contracts |
| Who pays |
Hospitals, surgical centers globally |
| Revenue model |
System placements (upfront or lease), instrument/accessory consumables (per procedure), annual service contracts |
| How sticky |
Extremely high — hospitals train entire surgical staff, $2M+ installation investment, 10+ year system life |
Key Segments
| Segment |
Revenue % |
Growth |
Notes |
| Instruments & Accessories |
~60% |
+18% YoY |
Highest-margin, recurring consumable revenue |
| Systems |
~25% |
+12% YoY |
New da Vinci 5 placements |
| Services |
~15% |
+10% YoY |
Annual maintenance contracts |
Competitive Analysis
Competitive Moat
| Moat Type |
Present? |
Evidence |
| Switching costs |
🟢 |
Surgeon training 12-18 months, hospital capital commitment |
| Intangible assets |
🟢 |
10,000+ patents, FDA approvals, 30+ years surgical data |
| Network effects |
🟢 |
More procedures = more outcome data = hospital confidence = more placements |
| Cost advantages |
🟡 |
Premium pricing but justified by outcomes |
| Efficient scale |
🟢 |
10,000+ installed systems globally, impossible to replicate quickly |
Moat Width: Wide
Moat Trend: Widening — da Vinci 5 (new generation) driving upgrade cycle
Competition
- Medtronic Hugo: Behind in FDA approvals, limited procedure indications
- J&J Ottava: In development, not yet commercial
- CMR Surgical (Versius): UK/EU only, lower margin
ISRG has 5-7 year runway before serious competition emerges.
Bull Case
Why This Could Work
- da Vinci monopoly — 10,000+ installed systems globally. No serious commercial competitor for 5+ years.
- Recurring consumable flywheel — Each installed system generates $500K-$1M+ annually in instruments.
- da Vinci 5 upgrade cycle — New generation driving hospital replacement purchases.
- Procedure growth — Robotic procedures growing 15%+ annually globally.
- RSI 8.8 = historical extreme — If still valid, no quality stock stays at RSI < 10 for 4-6 weeks without a material bounce.
Bear Case
What Could Go Wrong
- Insider selling persists — $282.6M net selling. Sustained supply suppressing price even at extreme RSI.
- Procedure volume miss — Hospital capex constraints slow system placements.
- da Vinci 5 adoption slower than expected — Upgrade cycle takes 3-5 years to complete.
- Regulatory issues — New FDA scrutiny on robotic surgery outcomes.
Thesis Killers
- Procedure growth rate drops below 8% for 2 consecutive quarters
- Major hospital system (Kaiser, Mayo) cancels orders for competitor
- Medtronic Hugo achieves FDA approval across major soft-tissue indications
Entry Strategy
Technical Levels
| Level |
Price |
Notes |
| Support 1 |
$455 |
Recent intraday lows (per stale data) |
| Support 2 |
$405 |
Stop-loss; below estimated 52wk low |
| Resistance 1 |
$527.40 |
SMA20 (stale) |
| Resistance 2 |
$575 |
3-month prior |
| 52-week high |
$592.85 |
In-window high |
Entry Approach
| Strategy |
Details |
| PRIORITY |
Refresh price data before any action |
| If RSI still < 15 |
1-2% starter position |
| If RSI 15-30 |
1% position, look for stabilization |
| Stop |
$405 (-15%) |
Research Log
| Date |
Update |
| 2026-02-16 |
Created deep dive. RSI 8.8 extreme. $476.32. Insider selling -$282.6M adds caution. Action: Buy (with caution). |
| 2026-02-22 |
Price refresh. $476.32 (flat). RSI 8.8 unchanged — 6+ days at extreme. -8.8% this week. -19.7% 30D. Continued RSI 8.8 without bounce is unusual — maintain reduced position size thesis. |
| 2026-02-26 |
OHLC data stale (last entry Feb 5). Price still $476.32 per available data. RSI 8.8 sustained for 3+ weeks. Action unchanged: Buy small size, be patient. |
| 2026-03-03 |
OHLC data still stale (last entry still Feb 5, 2026). Now 4 weeks without refresh. Data quality is the primary risk. Price/RSI unknown. No action until fresh data obtained. |
The Gold
Key Discoveries
| Discovery |
Implication |
| RSI 8.8 sustained 4+ weeks (if valid) |
Either most extreme persistent oversold in our tracking history, or data is stuck |
| OHLC data not refreshing for 4 weeks |
Data quality problem — ISRG may need manual fetch or different data source |
| da Vinci 5 upgrade cycle underway |
Long-term fundamentals remain excellent regardless of short-term price |
| Insider selling $282.6M net |
Management reducing exposure — pattern continues from prior reports |
Open Questions
- CRITICAL: What is the actual current price and RSI?
- Has ISRG bounced from $476.32 (last known price) since Feb 5?
- Are the insider sales on a pre-planned 10b5-1 schedule or discretionary?
- What is the da Vinci 5 system placement pace vs expectations?
- Is RSI staying at 8.8 due to index rebalancing / ETF selling?
Mistakes (Don't Repeat)
| Mistake |
Lesson |
| Not fetching fresh OHLC data over 4 updates |
Refresh price data every time before updating this file |
| Acting on stale RSI data |
4-week-old RSI is meaningless for trading decisions |
Sources
- Fundamentals figures: company-reported results (quarterly/annual filings) as available at the artifact date; predates the desk's EDGAR reconciliation gate — figures not re-verified after publication.